Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Bibliographic Details
Main Authors:	I. Vaxman, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, S. Hayman, T. Kourelis, R. Warsame, Y. Hwa, A. Fonder, M. Hobbs, E. Muchtar, N. Leung, P. Kapoor, R. Go, Y. Lin, W. Gonsalves, M. Siddiqui, R. A. Kyle, S. V. Rajkumar, M. A. Gertz, A. Dispenzieri
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-05-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00859-x

Similar Items

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
by: I. Vaxman, et al.
Published: (2022-06-01)

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
by: Charalampos Charalampous, et al.
Published: (2023-12-01)

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP
by: N. Abdallah, et al.
Published: (2022-06-01)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
by: Sarah Goldman-Mazur, et al.
Published: (2022-12-01)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
by: Alissa Visram, et al.
Published: (2021-11-01)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
by: Aimaz Afrough, et al.
Published: (2023-10-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES
by: Charalampos Charalampous, et al.
Published: (2023-08-01)

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
by: Abdullah S. Al Saleh, et al.
Published: (2022-04-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
by: H. Quach, et al.
Published: (2022-06-01)

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
by: Utkarsh Goel, et al.
Published: (2024-03-01)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
by: Utkarsh Goel, et al.
Published: (2023-01-01)

Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
by: Alissa Visram, et al.
Published: (2020-12-01)

Muscle and fat composition in patients with newly diagnosed multiple myeloma
by: Nadine H. Abdallah, et al.
Published: (2023-12-01)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
by: Walker M. Schmidt, et al.
Published: (2023-08-01)

Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome
by: Eli Muchtar, et al.
Published: (2022-06-01)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
by: Philippe Moreau, et al.
Published: (2023-03-01)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Published: (2023-03-01)

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES
by: H. Quach, et al.
Published: (2020-11-01)

Mode of progression in smoldering multiple myeloma: a study of 406 patients
by: Nadine H. Abdallah, et al.
Published: (2024-01-01)

MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
by: Patrick W. Mellors, et al.
Published: (2021-03-01)

Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
by: Patrick W. Mellors, et al.
Published: (2021-06-01)

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
by: V. Montefusco, et al.
Published: (2023-05-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
by: Saurabh Zanwar, et al.
Published: (2022-11-01)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
by: Jew Win Kuan, et al.
Published: (2022-01-01)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
by: Xavier Leleu, et al.
Published: (2023-08-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

Conditional survival in multiple myeloma and impact of prognostic factors over time
by: Nadine H. Abdallah, et al.
Published: (2023-05-01)

Pomalidomide-induced hypothyroidism
by: Sulaiman Haji Ali, et al.
Published: (2017-12-01)

A simple additive staging system for newly diagnosed multiple myeloma
by: Nadine H. Abdallah, et al.
Published: (2022-01-01)

P847: MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT GENERATION SEQUENCING IN BONE MARROW IN A PHASE 2 STUDY OF DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR MULTIPLE MYELOMA
by: B. Derman, et al.
Published: (2022-06-01)

P921: ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS FOR RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Jacob Shreve, et al.
Published: (2023-08-01)

PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
by: Tassia Cristina Decimoni, et al.
Published: (2023-08-01)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
by: C. Touzeau, et al.
Published: (2022-06-01)

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
by: Faouzi Djebbari, et al.
Published: (2022-12-01)

EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001
by: X. Leleu, et al.
Published: (2020-11-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)